Longevity & Aging · Metabolic & Cardiometabolic
rapamycin increases healthspan and lifespan
In plain terms: Is rapamycin proven to make animals live longer also proven to extend human lifespan?
Robustly extends lifespan/healthspan in mice across independent labs, but in humans only short-term safety and immune-biomarker data exist — no human longevity outcome, exactly as Attia's hedged framing states.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Moel 2025 · Aging (Albany) | RCT | mixed | moderate | HUMAN: 48-wk intermittent low-dose rapamycin in healthy adults (PEARL trial) — primary visceral-adiposity endpoint largely null, broadly safe; no longevity outcome, confirms human data remains short-term/insufficient. |
| Bitto 2016 · eLife | animal | supports | high | MOUSE: transient 3-month rapamycin in middle-aged mice increased life expectancy up to 60% and improved healthspan measures. |
| Weiss 2018 · Aging (Albany NY) | animal | mixed | moderate | Rapamycin caused measurable glucose intolerance in mice (partly reversible with metformin), highlighting metabolic trade-offs that temper the healthspan claim. |
| Strong 2020 · Aging Cell | animal | supports | high | MOUSE: late-life (20mo) rapamycin raised survival in genetically heterogeneous mice; NIA-ITP multi-site design, sex-specific dosing effects. |
| Mannick 2018 · Sci Transl Med | RCT | mixed | high | HUMAN: TORC1 inhibitor (RAD001+BEZ235) in 264 elderly reduced infection rates and boosted immunity over 6 wks — biomarker/healthspan proxy, NOT a lifespan outcome; supports human tolerability, confirms absence of longevity endpoint. |
| Strong 2016 · Aging Cell | animal | supports | high | ITP dose-finding confirmed reproducible lifespan extension by rapamycin (and rapamycin+metformin) in heterogeneous mice, underscoring robustness of the animal effect. |
| Harrison 2009 · Nature | animal | supports | high | Rapamycin started late in life extended median and maximal lifespan in genetically heterogeneous mice at three independent sites, the landmark mammalian result. |
| Herrera 2023 · J Gerontol A | animal | supports | moderate | MOUSE: early or late-life rapamycin improved physical performance and reduced cardiac hypertrophy in aged mice (healthspan, not lifespan endpoint). |
| Arriola Apelo 2016 · J Gerontol A | animal | supports | moderate | MOUSE: intermittent rapamycin from 20 months extended lifespan in female C57BL/6J mice with reduced metabolic side effects. |
| Mannick 2014 · Sci Transl Med | RCT | mixed | moderate | HUMAN: RAD001 improved influenza vaccine response about 20% in elderly — immunosenescence proxy only, no aging/lifespan outcome. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.